350 related articles for article (PubMed ID: 21633010)
1. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.
Herschkowitz JI; Zhao W; Zhang M; Usary J; Murrow G; Edwards D; Knezevic J; Greene SB; Darr D; Troester MA; Hilsenbeck SG; Medina D; Perou CM; Rosen JM
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2778-83. PubMed ID: 21633010
[TBL] [Abstract][Full Text] [Related]
2. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
3. Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers.
Fougner C; Bergholtz H; Kuiper R; Norum JH; Sørlie T
Breast Cancer Res; 2019 Jul; 21(1):85. PubMed ID: 31366361
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.
Pfefferle AD; Agrawal YN; Koboldt DC; Kanchi KL; Herschkowitz JI; Mardis ER; Rosen JM; Perou CM
Dis Model Mech; 2016 Jul; 9(7):749-57. PubMed ID: 27149990
[TBL] [Abstract][Full Text] [Related]
5. Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models.
Dunlap SM; Chiao LJ; Nogueira L; Usary J; Perou CM; Varticovski L; Hursting SD
Cancer Prev Res (Phila); 2012 Jul; 5(7):930-42. PubMed ID: 22588949
[TBL] [Abstract][Full Text] [Related]
6. Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential.
Knezevic J; Pfefferle AD; Petrovic I; Greene SB; Perou CM; Rosen JM
Oncogene; 2015 Dec; 34(49):5997-6006. PubMed ID: 25746005
[TBL] [Abstract][Full Text] [Related]
7. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.
Knight JF; Lesurf R; Zhao H; Pinnaduwage D; Davis RR; Saleh SM; Zuo D; Naujokas MA; Chughtai N; Herschkowitz JI; Prat A; Mulligan AM; Muller WJ; Cardiff RD; Gregg JP; Andrulis IL; Hallett MT; Park M
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):E1301-10. PubMed ID: 23509284
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
Prat A; Parker JS; Karginova O; Fan C; Livasy C; Herschkowitz JI; He X; Perou CM
Breast Cancer Res; 2010; 12(5):R68. PubMed ID: 20813035
[TBL] [Abstract][Full Text] [Related]
9. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Prat A; Karginova O; Parker JS; Fan C; He X; Bixby L; Harrell JC; Roman E; Adamo B; Troester M; Perou CM
Breast Cancer Res Treat; 2013 Nov; 142(2):237-55. PubMed ID: 24162158
[TBL] [Abstract][Full Text] [Related]
10. Lunatic Fringe and p53 Cooperatively Suppress Mesenchymal Stem-Like Breast Cancer.
Chung WC; Zhang S; Challagundla L; Zhou Y; Xu K
Neoplasia; 2017 Nov; 19(11):885-895. PubMed ID: 28938159
[TBL] [Abstract][Full Text] [Related]
11. EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice.
Morel AP; Hinkal GW; Thomas C; Fauvet F; Courtois-Cox S; Wierinckx A; Devouassoux-Shisheboran M; Treilleux I; Tissier A; Gras B; Pourchet J; Puisieux I; Browne GJ; Spicer DB; Lachuer J; Ansieau S; Puisieux A
PLoS Genet; 2012; 8(5):e1002723. PubMed ID: 22654675
[TBL] [Abstract][Full Text] [Related]
12. Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization.
Sabatier R; Finetti P; Guille A; Adelaide J; Chaffanet M; Viens P; Birnbaum D; Bertucci F
Mol Cancer; 2014 Oct; 13():228. PubMed ID: 25277734
[TBL] [Abstract][Full Text] [Related]
13. The miR-200b/200a/429 cluster prevents metastasis and induces dormancy in a murine claudin-low mammary tumor cell line.
Watson KL; Jones RA; Bruce A; Moorehead RA
Exp Cell Res; 2018 Aug; 369(1):17-26. PubMed ID: 29702103
[TBL] [Abstract][Full Text] [Related]
14. Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature.
Franks SE; Campbell CI; Barnett EF; Siwicky MD; Livingstone J; Cory S; Moorehead RA
Oncogene; 2012 Jul; 31(27):3298-309. PubMed ID: 22020329
[TBL] [Abstract][Full Text] [Related]
15. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.
Iwanaga R; Wang CA; Micalizzi DS; Harrell JC; Jedlicka P; Sartorius CA; Kabos P; Farabaugh SM; Bradford AP; Ford HL
Breast Cancer Res; 2012 Jul; 14(4):R100. PubMed ID: 22765220
[TBL] [Abstract][Full Text] [Related]
16. Murine microenvironment metaprofiles associate with human cancer etiology and intrinsic subtypes.
Nguyen DH; Fredlund E; Zhao W; Perou CM; Balmain A; Mao JH; Barcellos-Hoff MH
Clin Cancer Res; 2013 Mar; 19(6):1353-62. PubMed ID: 23339125
[TBL] [Abstract][Full Text] [Related]
17. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer.
Liu JC; Voisin V; Bader GD; Deng T; Pusztai L; Symmans WF; Esteva FJ; Egan SE; Zacksenhaus E
Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5832-7. PubMed ID: 22460789
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
[TBL] [Abstract][Full Text] [Related]
19. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
Hennessy BT; Gonzalez-Angulo AM; Stemke-Hale K; Gilcrease MZ; Krishnamurthy S; Lee JS; Fridlyand J; Sahin A; Agarwal R; Joy C; Liu W; Stivers D; Baggerly K; Carey M; Lluch A; Monteagudo C; He X; Weigman V; Fan C; Palazzo J; Hortobagyi GN; Nolden LK; Wang NJ; Valero V; Gray JW; Perou CM; Mills GB
Cancer Res; 2009 May; 69(10):4116-24. PubMed ID: 19435916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
